Beta 2 Microglobulin-Knockout (B2M-KO) iMSC cell therapy(Eterna Therapeutics)

N/A

Report date: 2024/07/09 17:49:51

Base Information

Drug NameBeta 2 Microglobulin-Knockout (B2M-KO) iMSC cell therapy(Eterna Therapeutics)
Drug Alias NameB2M-KO iPSC-derived iMSC therapy(Eterna Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesErnexa Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesErnexa Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A